HE INACTIVATION OF the multiple tumor-suppressor gene 1 (MTSlIp16'NK'A, CDKN2)'2* and multiple tumor-suppressor gene 2 (MTS2Ipl 5'NK4B)2,3 has frequently been shown in a large variety of human tumor cell lines.*,' Both genes are located at chromosome 9p21, a region that has been shown by cytogenetical analysis to be deleted in approximately 10% of T-cell acute lymphoblastic leukemia (T-ALL).s,6 MTSI contains four exons that generate two types of transcripts (here named MTSla and MTSIO) initiated from distinct promoters.""' MTSlu includes exon lu, exon 2, and exon 3 and encodes the ~1 6 '~~~~ protein. MTS l@ (exon I@, exon 2, and exon 3) encodes a 132 amino acid polypeptide ( F~1 6~ or ~1 9~~" ' ) that arises in major part from an alterative reading frame of the MTSl gene and that is unrelated to p16INK4". MTS2 contains two exons, which encode the ~1 5 '~~~~ protein. MTS2 exon 2 displays extensive sequence homology with MTSI exon 2. p16INK4" and p1 5INK4' inhibit the activity of cyclin-dependent kinases (cdk) 4 and 6, which control progression through the G1 phase of the cell cycle."," Ectopic expression of in rodent fibroblasts induces G1 and G2 phase arrest." Studies based on primary tumor cells have shown that inactivation pattern of MTSl exons la and 2 was found and MTSl RNA was detected in the fourth case, but a rearrangement occurring 5' t o MTSl exon 1 a deleting MTSl exon 1p was documented. One case presented a complex rearrangement. Germline configuration for MTSl and MTS2 was found in only 7 cases. The localization of the 17 breakpoints occurring in the MTS locus were determined. Ten of them (59%) are clustered in a 6-kb region located 5 kb downstream to the newly identified MTSl exon lp. No rearrangement disrupting MTS2 was detected and more rearrangements spared MTSZthan MTSl ( P < .01). MTSl but not MTS2RNA was detected by Northern blotting in the human thymus. These data strongly suggest that MTSl is the functional target of rearrangements in T-ALL. MTSl inactivation, observed in at least 80% of T-ALL, is the most consistent genetic defect found in this disease t o date. 0 1996 by The American Society of Hematology.
of MTSI is predominantly found in a restricted number of tumor cell types (for a review see Hirama et all'), including acute lymphoblastic
Since the initial studies describing the high incidence of MTSl homozygous deletions in human ALL,'4.'' a number of studies have confirmed that these events represent an important marker of this di~ease.'~.'~ The notion that MTSI inactivation is more frequent in T-ALL than in B-lineage ALL found in our initial series'' has been subsequently confirmed by somer8.20322 but not all'h~'7~" studies. Moreover, it was not clear from the available literature how frequently MTSl was inactivated on the second allele in T-ALLs with hemizygous MTSl deletion or intragenic rearrangement.
The present study was therefore performed (1) to establish a detailed restriction map of the MTS locus allowing a precise description of the structural events involving MTS genes, (2) to determine the frequency of MTSl homozygous deletions in a large single-center series of T-ALLs, (3) to localize the chromosomal breakpoints that occur in the MTS locus in T-ALL, and (4) to analyze T-ALL cases with hemizygous deletions or rearrangements.
Our results establish that MTSl inactivation is the most consistent genetic defect found in T-ALL to date.
MATERIALS AND METHODS

Patients and cells.
This single-center study is based on a cohort of patients referred to St Louis Hospital (Paris, France). From January 1985 to March 1995, the diagnosis of ALL was made in 655 patients, including 488 new cases. These 488 patients include 330 children (516 years of age) and 158 adults. In more than 90%, bone marrow and/or peripheral blood samples were cryopreserved. Diagnosis of ALL was made according to standard procedures." Immunophenotyping was performed by a combined approach of cytofluorometry and irnmunocytology, as described.26 Sixty-six cases of T-ALL were diagnosed in children (20% of all pediatric ALL) and had the following characteristics: median age, 9 years; cases with white blood cell count (WBC) greater than 30 X I O y k , 82%: sex ratio (Mm), 4.7. Thirty-nine T-ALL cases were diagnosed in Cryopreserved cells from 59 patients (40 children and 19 adults) with T-ALL were studied ( Table 1 ). This series includes 43 patients randomly selected from our cell collection (January 1985 to December 1991) and 16 patients with T-ALL consecutively referred for diagnosis and/or therapy at our institution (from January 1992 to December 1994). Forty-seven cases were studied at presentation, 7 cases at relapse, and 5 cases both at presentation and at relapse.
The T-ALL-derived Molt 4 cell line, the B-lineage ALL-derived RS4.11 cell line (American Tissue and Cell Collection CRL 1873), and the epithelial-derived Hela cell line were used in some experiments.
DNA probes. MTSf exon 2 and exon 1 probes have previously been described." Other probes were designed for the work reported here. A MTSl exon 3 probe was obtained by the polymerase chain reaction (PCR) on genomic DNA using the following primers: 5'-CCGGAATTCAGACATCCCCGATTGAAA-3' and 5"CCGGAA-TTCACAATAAATGAGTGAATGAATGAA-3'. A 290-bp DNA fragment from the MTS2 exon 1 was amplified from complementary DNA obtained after reverse transcription of Hela total RNA using the CDK22 (sense) and CDK23 (antisense) primers (CDK22, GAC). C5.3,2.3, and 2.7 sequence-tagged sites (STS) were amplified using previously described primers.* PCR products were cloned in the plasmid PCR-Script SK(+) (Stratagene, La Jolla, CA) and used as probes. MTSI-exon 1, MTSf-exon 3, C5.3, 2.7, and MTS2-exon 1 probes recognize unique sequences in genomic DNA. The MTSfexon 2 probe recognizes both MTSf-exon 2 and MTS2-exon 2 sequences, as shown." The 2.3 probe recognizes weakly repeated sequences in genomic DNA but a unique sequence in the MTS locus (unpublished observations).
Restriction map of the MTS locus (Fig IA) . The map of the MTS locus (extending over approximately 55 kb) proposed by Kamb et aI2 was corrected and greatly extended using various strategies. P1 clones spanning the locus were obtained by screening the Du Pont Merck Pharmaceutical CO Human Foreskin Fibroblast PI Library 1 (Genome Systems, St Louis, MO) by the PCR using the following MTSf -specific primer sequences: 5'-GGAAATTGGAAACTG-GAAGC and 5"CTGCCCATCA TCATGACCTG. PI phage clones were studied by Southern blot analysis and by long-range PCR (XL PCR kit; Perkin Elmer, Foster City, CA). Positions of MTSf exons, MTS2 exons, STS C5.3, STS 2.3, and STS 2.7 were determined by multiple digestion analysis using internal restriction sites (Fig 1.4) . Results obtained on P1 phages, subclones, restriction fragments, and PCR fragments were verified on normal genomic DNA. Some discrepancies were observed with the previously published Southern blotting analysis of MTS lMTS2 rearrangements. Southern blots were performed according to standard methods.*' As an initial screening, EcoRI digests were hybridized to the MTSIexon 2 probe." Additional simple or double digests (HindIII, BamHI, Kpn I, and Sal I essentially) were used in selected experiments and CTITGAGCTCGGCTGCGTC; CDK23, ATTCCGCAGCCCCCAprobes MTSI-exon 1, MTSf-exon 3, C5.3, 2.7, and MTS2-exon 1 were used in 54, 22, 38, 29, and 43 cases, respectively. Partial data from 24 patients have previously been published."
Single-strand conformation polymorphism (SSCP) analysis of MTSl exon I and exon 2. MTSI-exon 1 was amplified using sense primer 2F and reverse primer 1 108R, which yielded a PCR product of 336 bp.' MTSI-exon2 was amplified using sense primer GGT-AATTAGACACCTGGGGC corresponding to nucleotide 71 to 90 of the CDKI sequence published by Nobori et a14 and reverse primer 551R: which yielded a PCR product of 480 bp. Amplifications were performed in the presence of 10 pCi/lOO pL of 32P dCTP. PCR products were heat denatured and electrophoresed in 0% MDE gels (Bioprobe Systems, Montreuil-sous-Bois, France) at 8 W for 14 hours. Gels were dried and autoradiographed. For T99r and T109 samples, MTSI-exon 2 PCR products were cloned in the PCR Script SK(+) vector and two independent clones were sequenced (data not shown). As a control, two new MTSl exon 2 amplifications were dot-blotted on a Hybond N+ membrane (Amersham International plc, Buckinghamshire, UK) and successively hybridized with 32P-labeled oligonucleotides recognizing wild-type: (GCGATGCCT-GGGGCCGTC) or mutated (GCGATGCCTGAGGCCGTC) alleles.
Northern blotting analysis of MTSlMTS2 expression. Northern blots were prepared as describedz7 from polyA+-enriched RNA extracted from patient samples. In addition, a commercially available blot prepared from diverse human tissues (Clontech Lab Inc, Palo Alto, CA) was used. The MTSf-exon 3 probe was used to detect MTSI RNA. This probe detects all the MTSf species in the Hela cell line (unpublished observation). The MTS2-exon 1 probe was used to detect MTS2 expression. This probe does not cross-hybridize with MTSf sequences. RNA integrity and loading were evaluated on ethidium bromide-stained gels and on stripped blots hybridized to a pACTIN or NADPH probe.
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RESULTS
Conjguration of the MTS locus in T-ALL. The configuration of the MTS locus was studied by Southern blotting analysis. Data were analyzed by comparison with the restriction map shown in Fig 1A. A representative experiment is shown in Fig 2 and all data are summarized in Table 1 and Fig 1B. All but 1 case (with a complex and not fully characterized rearrangement) were classified according to the configuration of MTSl and MTS2.
In 45 cases (76%), both copies of MTSl were inactivated by deletion (44 cases) or intragenic rearrangement (1 case; T98) defining the type I configuration. Both MTS2 copies were deleted in 35 cases (type Ia), whereas one single copy of MTS2 was deleted in 10 cases (type Ib).
One complete copy of MTSl (including exon l@) is pres- I I E -3 1 6 , ex3 ex2 e x l a c5.3 2.3 2.7 (ex1P)exZ ex1
."""""""""""""""""""""""""""""""""- copy of MTS I exon la, MTSl exon 2, and MTSl exon 3 was detected, whereas MTSI exon Iox was deleted on this chromosome (type 111). Thus, monoallelic alterations of at least one of the three exons (exon la, 2, and 3) that code for ~1 6 '~~~~ were found in 6 cases (10%). In 7 cases, a germline configuration was detected for both copies of MTSl and MTS2 (type IV configuration).
Incidence of the different types of configuration is similar in the pediatric (40 cases) and adult (19 cases) series. Type I configuration was observed in 30 of 40 cases in children (75%) and 15 of 19 cases in adults (79%; Table 1 ).
Comparison of the random series (43 cases) with the consecutive series (16 cases) did not detect a statistically significant difference, although the proportion of type I configuration appeared to be slightly higher in the random series than in the consecutive series (35 of 43 cases and 10 of 16 cases, respectively; P = .IS, not significant, by the x2 test).
Age, cytological (French-American-British [FAB]") subtypes, and immunologic markers did not differ significantly in the three groups of patients (data not shown).
In the 5 cases with samples available at presentation and relapse, 4 were unmodified and 1 was a type I1 at presentation (T39p) and Ib at relapse (T39r).
Localization of the breakpoints in the MTS locus. In 34 samples with a biallelic MTS deletion, deletion analysis showed that the breakpoints fell outside the MTS locus ( Fig   In 15 samples with partial deletion of the MTS locus, plus the Molt4 cell line, the precise localization of 17 breakpoints (2 breakpoints in the sample T106 fell within the MTS locus) was obtained by Southern analysis (Fig IB) . One breakpoint occurred between exon la and exon 2 (T98). another between exon 2 and exon 3 (T81), and two breakpoints were localized immediately 5' to MTSI exonla (T39p and T106). The 13 other breakpoints were localized between MTSl exon la and MTSl exon 10, with 10 (59% of all breakpoints) being located between STS 2.3 and STS 2.7. No breakpoint disrupting MTS2 was observed.
Rearrangements were analyzed with respect to the alteration of the coding potentials of MTSl and MTS2. Two rearrangements sparing MTSI exon la, MTSl exon 2, and MTSl exon 3 (which collectively encode the p16INK4" protein from RNA initiated immediately 5' to exon la) were observed (T39p and T106), whereas 14 rearrangements sparing all MTS2 exons were detected (Fig IB, P < Fig 1A) . This probe detects a rearranged fragment in the three digests allowing localization of the breakpoint between the STS 2.3 and the STS 2.7 ( Fig 1B) . The asterisk indicates polymorphic BamHl fragment in contaminating nonneoplastic cells. This polymorphic site is not present in the rearranged allele.
2.7
included in the analysis, because no rearrangement spares all MTSl exons (Fig IB) .
SSCP and Northern blot ana1we.v of T-ALLY with hemizygous a1terotion.s cJf MTS1. To detect mutations that may inactivate the second MTSl allele. SSCP analysis of MTSI exon 1 and exon 2 was performed in 4 cases with a type I1 configuration (T81, T94, T99r. and T109) and in 1 case with a type 111 configuration (T39p; see Fig 1 B for the configuration of the MTS locus in these cases). Five cases with a normal (type IV) configuration were also studied as controls.
A normal MTSl exon I SSCP pattern was found in all I O cases. An abnormal and identical MTSI exon 2 pattern was detected in 2 cases with a type 11 configuration (T99r and T109; Fig 3A) . The MTSl exon 2 nucleotide sequence was determined in these 2 cases and showed an identical mutation leading to a stop codon located at the beginning of the fourth ankyrin domain of p16'"KJ" (Fig 3B) and to a Gly124 to Arg124 substitution in the predicted aminoacid sequence of pl9ARF. Several controls were performed to be sure that the same mutation was present in the tumor cells of the 2 patients: ( 1 ) molecular HLA DQ typing showed that the two DNA samples used came from 2 different patients (courtesy of Dr P. Loiseau, Laboratory of Histocompatibility, St Louis Hospital, Paris, France) and (2) SSCP and hybridization experiments were performed twice with consistent results. Results shown in Fig 3A and C provide good evidence against PCR contamination, because no germline sequences were detected in these cases that both display one MTSI exon 2 copy on Southern blots (data not shown).
A normal SSCP pattern was thus found in cases T8 I, T94 (type II), and T39p (type 111). Northern blot analysis of MTSl RNA expression was performed on polyA+-enriched RNA in cases T81 and T39p (in which material was available) to search for transcriptional activity of the intact MTSl allele. No significant expression was found in the T81 sample, whereas high levels of expression were detected in the T39p case (Fig 4) . MTS 1 and MTS2 mRNA expression in the human thynus (Fig 5) . The high frequency of MTS gene inactivation in T-ALL suggests that MTSl and MTSZ may play an important role in thymocytes. MTSl and MTSZ mRNA expression was studied by Northern blotting of thymic mRNA and various other human tissues. Clear expression was found in the thymus and spleen and strong expression of a small-sized MTSl mRNA was found in the testis. A very faint signal was detected in peripheral blood lymphocytes, colon, small intestine, ovary, and prostate. By contrast, no MTS2 signal was found in the thymus. Faint MTS2 RNA signals were detected in other tissues and a small-sized RNA was found in the testis.
DISCUSSION
In this study, we have reported a Southern blot analysis of the MTS locus in 59 T-ALLs. An important finding of this work was the demonstration that both copies of corresponding t o the wild sequence (1) and the mutated sequence (2) . Duplicate experiments are shown. PBL, peripheral leukocytes from an healthy donor; C, no DNA. frequency in T-ALL are unclear. Identification of homozygous deletions in cases with admixture of neoplastic and normal cells is difficult and may have led to an underestimation of homozygous deletions in some studies. We have included dilution experiments in all our Southern blot studies and carefully compared the intensity of residual bands with the percentage of neoplastic cells. As shown in this study and others,'x,2"'2 MTSI homozygous deletions with persistence of at least one MTS2 allele are not uncommon. To identify the restriction fragments, we have established a detailed restriction map of the locus and used a large panel of probes. With the exception of 1 case, we were able to precisely define the MTS configuration in all cases and are confident with our evaluation, which has been confirmed in selected cases by Western blot analyses of M T s l /~l 6 '~~~" protein expression (23 T-ALL cases tested; unpublished data).
Patient selection is another point that may explain variations among the results reported in the literature. Characteristics of the patients referred to our laboratory (see Materials and Methods) are similar to those of other large clinical found in samples randomly selected from our cell collection, but also in consecutive cases. Because we have found a similar percentage of MTSl homozygous deletions in adult and pediatric series (79% and 75%, respectively), age is unlikely to be a critical factor explaining differences among studies. probes.
For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From In addition to this report, two recent studies have analyzed the frequency of MTSl homozygous deletions in series including more than 20 patient~.".~~ A 39% incidence (22 of 56 cases) was found in the series from Ohnishi et alz4 based on Japanese patients. In the work from Takeuchi et alzz based on patients from the Multicenter ALL BFM 86 and 90 trials on childhood ALL of the German Berlin Frankfurter Munster (SEW) group, an incidence similar to that we have found was observed (17 of 22 cases [77%]). Whatever the actual figure, MTSl inactivation is clearly the most prevalent molecular abnormality described to date in T-ALL, with the SIL-TAL1 deletion occurring in less than 20% of cases (10 of 59 cases in this series [17%]; unpublished data).
This work is the first attempt to determine whether chromosomal breakpoints occur at random or not within the MTS locus. Seventeen breakpoints (16 from T-ALL samples and 1 from the Molt4 cell line) have been localized. Interestingly, 10 of them are clustered in a 6-kb region, suggesting the presence in this region of sequences promoting the recombination. All breakpoints are located downstream of a newly identified MTSl exon and upstream to MTSl exon 3 and lead therefore to the disruption of the gene.
Although deletions and rearrangements are the most prevalent events inactivating MTS 1 in T-ALL, other mechanisms occur in some cases. In 6 cases of this series, a monoallelic alteration of at least one of the MTS 1 exons la, exon 2, and exon 3 was detected. In two of these cases, a point mutation introducing a stop codon at the beginning of the fourth ankyrin domain of the ~1 6 '~~~~ protein was found. This location is a hot spot for nonsense mutations in nonhematopoietic tumors.2.30 Interestingly, deletion of the fourth ankyrin repeat abolishes ~1 6 '~~~~ activity ~ompletely.~' To date, MTSl point mutations occurring in T-ALL have been described in only one studyz4 in which 4 mutations either in the first MTSI intron (1 case) or in the MTS 1 exon 2 (3 cases) were found. The status of Ihe second MTSI allele was not defined in this study. MTSl transcriptional inactivation is another mechanism that has been suggested to occur in primary cells from lung carcinorna~.~~ One case from our series (T81) displays this phenotype. In this case, the SSCP analysis was normal, but only a barely detectable level of MTSl RNA was detected. Methylation of the CpG island located upstream to MTSl exon la was analyzed and a nonmethylated pattern was found (unpublished data), showing that transcriptional inactivation is not due, in this case, to the acquired hypermethylation observed in other types of tumors.32
The high frequency of MTSl inactivation in T-ALL, the finding of point mutations and transcriptional inactivation in some cases with a monoallelic deletion, and the demonstration of the antioncogenic effect of the MTSl/p16'NK4A protein make this gene the probable functional target of MTS locus alterations. Recently, a new MTSl transcript (MTSlp) has been de~cribed."~ It includes MTSl exon l@, MTSl exon 2, and MTSI exon 3. This transcript has been shown to be expressed in many different tissues in mouse contrasting with the more restricted expression pattern of MTS la. Io Its nucleotide sequence contains two open reading frames (ORF). The first ORF would encode a protein of 105 amino acids corresponding to 2.75 of the 4 ankyrin repeats of the ~1 6 '~~~~. Its start codon is flanked by a sequence that is not a good match with the consensus Kozak sequence. The second O W encodes for a product of approximately 22 kD (pl9AW). It is interesting that the ability to express this protein has been lost in all the T-ALL cases we have analyzed in which at least one structural event has been detected in the MTS locus (ie, types I, 11, and 111). It remains therefore unclear which protein(s) of and is the functional target of MTSl locus alterations.
Although MTSl is one probable functional target of MTS locus alterations, it remains possible that genes other than MTSl are targeted by this process. MTS2 located approximately 30 kb 5' to the MTSI-exon la (this study, Fig 1A) is an obvious candidate. The product of this gene, p151NK4', shares identical biochemical properties with p16MK4A.3 However, several results suggest that MTSl is more important than MTSZ for T-ALL oncogenesis. (1) MTS2 inactivation is clearly less frequent than that of MTSI; biallelic inactivation of MTSZ has been found in only 36 cases (61%) of this series and breakpoints spared MTS2 significantly more frequently than MTSl (P < .Ol, by the x ' test). (2) No MTS2 structural alteration was found by Southern blot analysis in this study. (3) Hyperphosphorylated forms of Retinoblastoma gene protein product are found in T-ALL irrespective of the presence or absence of an intact copy of MTS2 (23 T-ALL cases tested; unpublished data). (4) MTSl mRNA is expressed in human thymus (albeit at a low level), whereas MTS2 mRNA is undetectable. Altogether, these data are consistent with the hypothesis of the predominant role of MTSl in T-ALL cells that probably derived from thymocyte^.^^
In conclusion, MTSl is inactivated in a very high percentage of T-ALLs. This defect, the most consistent acquired genetic defect found so far in this disease, could play a key role in the development of this human tumor and is an obvious target for future biologic therapies. For personal use only. on August 30, 2017 . by guest www.bloodjournal.org From
